Developer docs
API playgroundTry for free, no card

Search company profiles

Collaborative Trajectory Analysis Project

Full company profile

uuid000adq9

Namestring
Collaborative Trajectory Analysis Project
Legal namestring
Collaborative Trajectory Analysis Project
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Collaborative Trajectory Analysis Project (cTAP) is a Cambridge, MA-based precompetitive research coalition founded in 2017 and operating under the public-facing brand 'cTAP.' The organization aggregates longitudinal clinical data from Duchenne muscular dystrophy (DMD) patients across a network of 47 collaborating patient organizations, academic research centers, and industry partners. As of 2025, cTAP's data platform holds 18,000+ clinic visits, 7,500+ patient-years of follow-up, and records on 2,500+ boys and young men with DMD, supporting what the company describes as 'strategic, collaborative, non-competitive patient data science.'

The core products are the cTAP Duchenne Program — a shared trajectory data infrastructure for DMD — and the May 2026 cTAP Duchenne Loss of Ambulation Prognostic Score, a five-tier validated risk classifier published in Neurology that uses rise-from-floor and 10-meter walk/run assessments to stratify patients by median time to loss of ambulation. The organization has produced 15 peer-reviewed publications, 70 abstracts and posters, and 100+ scientific meetings, channeling outputs through academic publications, conferences, and direct stakeholder partnerships rather than commercial distribution.

cTAP is structured as a nonprofit coalition rather than a commercial entity. There is no product pricing, subscription, or fee model disclosed. Funding flows implicitly through collaborative research partnerships with patient organizations, industry sponsors, and research grants for precompetitive work; no equity funding rounds, parent company, or commercial revenue lines are disclosed. Leadership is led by founder and Executive Director Susan Ward. The operating footprint claims global reach, with a stated mission to accelerate research for approximately 300,000 people worldwide affected by rare neuromuscular diseases, and the website exposes a 'What's Next' program signaling potential expansion beyond DMD.

Short descriptiontext

Collaborative Trajectory Analysis Project (cTAP) is a Cambridge-based precompetitive research coalition founded in 2017 that aggregates longitudinal Duchenne muscular dystrophy patient data across 47 partner institutions and develops validated prognostic tools to accelerate rare neuromuscular disease research.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease research, patient data science, precompetitive research coalition, clinical trial design tools, neuromuscular disease research
Industry3 codes
PRIMARYHLACAHAH
Patient Registries & Chronic Disease Registry Analytics
Healthcare & Life Sciences/Digital Health & Health IT/Population Health Management & Value-Based Care Analytics
SECONDARYHLACAOAD
Clinical Trial Management Systems (CTMS)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAJANAG
Chronic Disease & NCD Program Evaluation (e.g., diabetes/CVD/cancer)
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Rare Disease Clinical Research Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Precompetitive Research Funding
TypeSubscription Recurring
Description

cTAP operates as a nonprofit coalition funded by patient organizations, industry partners, and research grants to conduct precompetitive research in rare neuromuscular diseases. Revenue appears to come from collaborative partnerships and research support rather than commercial product sales.

ctap-nmd.org
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

cTAP operates a precompetitive research coalition that aggregates and analyzes longitudinal patient trajectory data from rare neuromuscular disease patients (primarily Duchenne muscular dystrophy) across 47 collaborating institutions. It provides strategic, non-competitive patient data science, develops validated prognostic tools such as the Loss of Ambulation Prognostic Score, and supports clinical trial design and patient counseling through evidence-based disease progression models.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Prognostic score classifies DMD patients into five risk groups with median time to loss of ambulation ranging from over 4 years (lowest-risk) to 0.9 years (highest-risk)
Product overview1 text field

cTAP is a precompetitive research coalition that operates as a unified platform for patient data science in rare neuromuscular diseases. The core offering consists of the cTAP Duchenne Program, which provides a shared data infrastructure aggregating clinical trajectory data from thousands of patients across multiple institutions, complemented by specific prognostic tools like the Duchenne Loss of Ambulation Prognostic Score. These offerings work together to accelerate clinical research by enabling cross-stakeholder collaboration, strategic data support, and evidence-based prediction models for clinical trial design and patient counseling.

Product and service2 records
1cTAP Duchenne Program
CategoryClinical Research Program
Description

A collaborative research program focused on analyzing patient trajectory data for Duchenne muscular dystrophy. It aggregates clinical data from over 18,000 clinic visits, 7,500+ patient years of follow-up, and 2,500+ boys and young men with DMD across 47 collaborating institutions to accelerate research for rare neuromuscular communities.

2Duchenne Loss of Ambulation Prognostic Score
CategoryPrognostic Tool
Description

A validated prognostic tool that uses two functional assessments (rise from floor and 10-meter walk/run) to classify DMD patients into five risk groups, with median time to loss of ambulation ranging from over 4 years (lowest-risk) to 0.9 years (highest-risk). Developed from data on over 600 boys with DMD and validated on an independent dataset, it supports clinical decision-making, patient counseling, and clinical trial design.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
147 Collaborating Institutions and Organizations
Strategic tierCoreTypeStrategic or Co-development Partner
Description

cTAP maintains a coalition of 47 collaborating institutions and organizations contributing to and benefiting from the shared patient data platform. These include patient organizations, scientific leaders, researchers, and industry partners working collaboratively on precompetitive research in rare neuromuscular diseases.

ctap-nmd.org
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

C-Path is the largest US precompetitive research consortium, convening industry, regulators, academics, and patient groups to share data and build tools that accelerate therapeutic development across multiple disease areas. Like cTAP, it operates a coalition model focused on shared data science and regulatory-grade evidence.

TypeDirect peer
Description

Treat-NMD is an international neuromuscular disease network that aggregates patient data, runs registries (including for DMD), and supports clinical trial readiness. It overlaps cTAP directly in DMD natural-history data and neuromuscular trial enablement.

TypeDirect peer
Description

PPMD operates the Duchenne Registry, one of the most established patient-reported and clinical DMD data repositories in the US. It is directly comparable to cTAP as a DMD patient-data and advocacy-led research organization.

TypeRegional player
Description

Cincinnati Children's is a leading DMD research site with substantial longitudinal patient data and clinical-trial expertise. It is a major potential contributor/competitor to cTAP's data consortium model.

TypeBroad incumbent
Description

The CFF Patient Registry is the prototypical rare-disease longitudinal clinical registry used to inform trial design, drug approval, and outcomes research. It is a well-established comparator model for how a single-indication disease registry creates durable research infrastructure.

6CoRDS (Sanford Research Coordination of Rare Diseases)
TypeEmerging player
Description

CoRDS is a global rare-disease patient registry that collects de-identified data across multiple rare conditions, including neuromuscular diseases. It is comparable to cTAP's cross-institutional rare-disease data platform approach.

7FD/MAS Alliance & Related Registries
TypeOthers
Description

FD/MAS Alliance operates a patient registry and supports rare bone disease research through collaborative models, illustrating how rare-disease patient organizations are increasingly building structured longitudinal data assets, similar to cTAP's neuromuscular focus.

8Wellstone Muscular Dystrophy Research Centers
TypeDirect peer
Description

The NIH-funded Wellstone Centers focus on muscular dystrophy research, including DMD, and share patient-level data and resources across institutions. They are partial peers given their overlapping scientific scope but academic/government ownership model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Collaborative Trajectory Analysis Project

Rare Disease Clinical Research Servicesctap-duchenne.org

Collaborative Trajectory Analysis Project (cTAP) is a Cambridge-based precompetitive research coalition founded in 2017 that aggregates longitudinal Duchenne muscular dystrophy patient data across 47 partner institutions and develops validated prognostic tools to accelerate rare neuromuscular disease research.

What Collaborative Trajectory Analysis Project does

Collaborative Trajectory Analysis Project (cTAP) is a Cambridge, MA-based precompetitive research coalition founded in 2017 and operating under the public-facing brand 'cTAP.' The organization aggregates longitudinal clinical data from Duchenne muscular dystrophy (DMD) patients across a network of 47 collaborating patient organizations, academic research centers, and industry partners. As of 2025, cTAP's data platform holds 18,000+ clinic visits, 7,500+ patient-years of follow-up, and records on 2,500+ boys and young men with DMD, supporting what the company describes as 'strategic, collaborative, non-competitive patient data science.'

The core products are the cTAP Duchenne Program — a shared trajectory data infrastructure for DMD — and the May 2026 cTAP Duchenne Loss of Ambulation Prognostic Score, a five-tier validated risk classifier published in Neurology that uses rise-from-floor and 10-meter walk/run assessments to stratify patients by median time to loss of ambulation. The organization has produced 15 peer-reviewed publications, 70 abstracts and posters, and 100+ scientific meetings, channeling outputs through academic publications, conferences, and direct stakeholder partnerships rather than commercial distribution.

cTAP is structured as a nonprofit coalition rather than a commercial entity. There is no product pricing, subscription, or fee model disclosed. Funding flows implicitly through collaborative research partnerships with patient organizations, industry sponsors, and research grants for precompetitive work; no equity funding rounds, parent company, or commercial revenue lines are disclosed. Leadership is led by founder and Executive Director Susan Ward. The operating footprint claims global reach, with a stated mission to accelerate research for approximately 300,000 people worldwide affected by rare neuromuscular diseases, and the website exposes a 'What's Next' program signaling potential expansion beyond DMD.

Collaborative Trajectory Analysis Project firmographics

Firmographics
Name
Collaborative Trajectory Analysis Project
Legal name
Collaborative Trajectory Analysis Project
Website
https://ctap-duchenne.org
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Collaborative Trajectory Analysis Project (cTAP) is a Cambridge-based precompetitive research coalition founded in 2017 that aggregates longitudinal Duchenne muscular dystrophy patient data across 47 partner institutions and develops validated prognostic tools to accelerate rare neuromuscular disease research.
Ownership category
akta.pro rank

Collaborative Trajectory Analysis Project industry classification

Industry
Product category
Rare Disease Clinical Research Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLACAHAH
Patient Registries & Chronic Disease Registry Analytics
Healthcare & Life Sciences/Digital Health & Health IT/Population Health Management & Value-Based Care Analytics
SECONDARYHLACAOAD
Clinical Trial Management Systems (CTMS)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAJANAG
Chronic Disease & NCD Program Evaluation (e.g., diabetes/CVD/cancer)

Keywords

  • Rare disease research
  • Patient data science
  • Precompetitive research coalition
  • Clinical trial design tools
  • Neuromuscular disease research

Where Collaborative Trajectory Analysis Project is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Collaborative Trajectory Analysis Project business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Precompetitive Research Funding: cTAP operates as a nonprofit coalition funded by patient organizations, industry partners, and research grants to conduct precompetitive research in rare neuromuscular diseases. Revenue appears to come from collaborative partnerships and research support rather than commercial product sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Collaborative Trajectory Analysis Project product offering

Product offering

Core offering

cTAP operates a precompetitive research coalition that aggregates and analyzes longitudinal patient trajectory data from rare neuromuscular disease patients (primarily Duchenne muscular dystrophy) across 47 collaborating institutions. It provides strategic, non-competitive patient data science, develops validated prognostic tools such as the Loss of Ambulation Prognostic Score, and supports clinical trial design and patient counseling through evidence-based disease progression models.

Product overview

cTAP is a precompetitive research coalition that operates as a unified platform for patient data science in rare neuromuscular diseases. The core offering consists of the cTAP Duchenne Program, which provides a shared data infrastructure aggregating clinical trajectory data from thousands of patients across multiple institutions, complemented by specific prognostic tools like the Duchenne Loss of Ambulation Prognostic Score. These offerings work together to accelerate clinical research by enabling cross-stakeholder collaboration, strategic data support, and evidence-based prediction models for clinical trial design and patient counseling.

Differentiator

Problem solved

Functional benefit

Products and services

  • cTAP Duchenne Program A collaborative research program focused on analyzing patient trajectory data for Duchenne muscular dystrophy. It aggregates clinical data from over 18,000 clinic visits, 7,500+ patient years of follow-up, and 2,500+ boys and young men with DMD across 47 collaborating institutions to accelerate research for rare neuromuscular communities.
  • Duchenne Loss of Ambulation Prognostic Score A validated prognostic tool that uses two functional assessments (rise from floor and 10-meter walk/run) to classify DMD patients into five risk groups, with median time to loss of ambulation ranging from over 4 years (lowest-risk) to 0.9 years (highest-risk). Developed from data on over 600 boys with DMD and validated on an independent dataset, it supports clinical decision-making, patient counseling, and clinical trial design.

Quantifiable outcome

  • Prognostic score classifies DMD patients into five risk groups with median time to loss of ambulation ranging from over 4 years (lowest-risk) to 0.9 years (highest-risk)

Companies that use Collaborative Trajectory Analysis Project

Customer profile

Segments2 records

Ideal customer profiles2 records

Collaborative Trajectory Analysis Project technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Collaborative Trajectory Analysis Project partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • 47 Collaborating Institutions and OrganizationscoreStrategic or Co-development PartnercTAP maintains a coalition of 47 collaborating institutions and organizations contributing to and benefiting from the shared patient data platform. These include patient organizations, scientific leaders, researchers, and industry partners working collaboratively on precompetitive research in rare neuromuscular diseases.

Scale indicators8 records

Recent moves4 records

Expansion highlights4 records

Collaborative Trajectory Analysis Project competitors and assessment

Company assessment

Direct peers

  • Critical Path Institute (C-Path): C-Path is the largest US precompetitive research consortium, convening industry, regulators, academics, and patient groups to share data and build tools that accelerate therapeutic development across multiple disease areas. Like cTAP, it operates a coalition model focused on shared data science and regulatory-grade evidence.
  • Treat-NMD: Treat-NMD is an international neuromuscular disease network that aggregates patient data, runs registries (including for DMD), and supports clinical trial readiness. It overlaps cTAP directly in DMD natural-history data and neuromuscular trial enablement.
  • Parent Project Muscular Dystrophy (PPMD): PPMD operates the Duchenne Registry, one of the most established patient-reported and clinical DMD data repositories in the US. It is directly comparable to cTAP as a DMD patient-data and advocacy-led research organization.
  • Wellstone Muscular Dystrophy Research Centers: The NIH-funded Wellstone Centers focus on muscular dystrophy research, including DMD, and share patient-level data and resources across institutions. They are partial peers given their overlapping scientific scope but academic/government ownership model.

Regional players

Broad incumbents

  • Cystic Fibrosis Foundation Patient Registry: The CFF Patient Registry is the prototypical rare-disease longitudinal clinical registry used to inform trial design, drug approval, and outcomes research. It is a well-established comparator model for how a single-indication disease registry creates durable research infrastructure.

Emerging players

  • CoRDS (Sanford Research Coordination of Rare Diseases): CoRDS is a global rare-disease patient registry that collects de-identified data across multiple rare conditions, including neuromuscular diseases. It is comparable to cTAP's cross-institutional rare-disease data platform approach.

Others

  • FD/MAS Alliance & Related Registries: FD/MAS Alliance operates a patient registry and supports rare bone disease research through collaborative models, illustrating how rare-disease patient organizations are increasingly building structured longitudinal data assets, similar to cTAP's neuromuscular focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Collaborative Trajectory Analysis Project social profiles

Digital presence

Collaborative Trajectory Analysis Project financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Collaborative Trajectory Analysis Project leadership team

Management profile

Number of profiles

Profiles1 record

Collaborative Trajectory Analysis Project funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Collaborative Trajectory Analysis Project M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Collaborative Trajectory Analysis Project

What does Collaborative Trajectory Analysis Project do?

cTAP operates a precompetitive research coalition that aggregates and analyzes longitudinal patient trajectory data from rare neuromuscular disease patients (primarily Duchenne muscular dystrophy) across 47 collaborating institutions. It provides strategic, non-competitive patient data science, develops validated prognostic tools such as the Loss of Ambulation Prognostic Score, and supports clinical trial design and patient counseling through evidence-based disease progression models.

Is Collaborative Trajectory Analysis Project a public or private company?

Collaborative Trajectory Analysis Project is a private company. It is classified as unknown and is currently operating.

When was Collaborative Trajectory Analysis Project founded?

Collaborative Trajectory Analysis Project was founded in 2017. It employs 1 to 10 people.

Where is Collaborative Trajectory Analysis Project based?

Collaborative Trajectory Analysis Project is headquartered in Cambridge, United States, in the North America region.

How does Collaborative Trajectory Analysis Project make money?

One revenue line is on record: precompetitive Research Funding.

Who are Collaborative Trajectory Analysis Project's main competitors?

Direct peers on record are Critical Path Institute (C-Path), Treat-NMD, Parent Project Muscular Dystrophy (PPMD) and Wellstone Muscular Dystrophy Research Centers. Cincinnati Children's Hospital Medical Center - DMD Research Programs is listed as a regional player. Cystic Fibrosis Foundation Patient Registry is listed as a broad incumbent. CoRDS (Sanford Research Coordination of Rare Diseases) is listed as an emerging player. FD/MAS Alliance & Related Registries is listed as an others.

Does Collaborative Trajectory Analysis Project have an API?

No public API is recorded for Collaborative Trajectory Analysis Project.

What industry is Collaborative Trajectory Analysis Project in?

Collaborative Trajectory Analysis Project's product category is Rare Disease Clinical Research Services. Its primary akta.pro industry code is HLACAHAH, Patient Registries & Chronic Disease Registry Analytics, with a secondary code of HLACAOAD, Clinical Trial Management Systems (CTMS). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpacecTAP Announces Novel Prognostic Score Developed for Duchenne Muscular Dystrophy Patients Offers Improved Prediction of Loss of AmbulationThe Collaborative Trajectory Analysis Project (cTAP) announced publication of a novel, validated prognostic score for predicting loss of ambulation in patients with Duchenne muscular dystrophy, developed using data from over 600 boys with DMD and published May 26, 2026 in Neurology. The score uses two functional assessments — rise from floor and 10-meter walk/run — to classify patients into five distinct risk groups, with median time to loss of ambulation ranging from over 4 years in the lowest-risk group to 0.9 years in the highest-risk group. The tool was validated against an independent dataset and outperformed existing classification models, offering improved risk stratification for clinical decision-making and clinical trial design.Business Wire BlogcTAP Announces Novel Prognostic Score Developed for Duchenne Muscular Dystrophy Patients Offers Improved Prediction of Loss of AmbulationcTAP published a validated prognostic score for predicting loss of ambulation in Duchenne muscular dystrophy, based on rise from floor and 10-meter walk/run. The score stratified patients into five risk groups, with median time to loss of ambulation ranging from 0.9 to over 4 years. It outperformed existing models and was validated on an independent dataset.PR NewswireBeyond Traditional Placebo Controls in Rare Disease Clinical Trials: New cTAP Evidence Supports Patient-Centric AlternativesThe Collaborative Trajectory Analysis Project (cTAP) announced evidence supporting patient-centric alternatives to genetically matched placebo controls in Duchenne Muscular Dystrophy clinical trials, published in Neurology. The multi-institution, multi-national study of more than 700 DMD patients found that less than 2 percent of motor function change over a 48-week trial period is attributable to genotype class differences. The findings suggest that clinical trials could use more efficient designs such as mixed-genotype controls and platform trials, reducing the number of treatment-eligible children receiving placebo.GlobeNewswireSummit Joins cTAP in Collaborative Effort to Enhance the Development of Utrophin Modulators and Other Treatments for Duchenne Muscular DystrophySummit Therapeutics joined the Collaborative Trajectory Analysis Project (cTAP) to accelerate Duchenne muscular dystrophy drug development. Its lead utrophin modulator ezutromid is in a Phase 2 trial, with 24-week data expected in Q1 2018 and full 48-week data in Q3 2018.